Business

Pharmaceutical Merger Talks

Updated 2026-08-02 20:10 UTC 1 source Neutral

AstraZeneca is considering a $400 billion deal to merge with Bristol Myers Squibb, according to reports.

Coverage timeline — 1 article

CNBC

U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.

2026-08-02 20:00 UTC